These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 23772631)
1. Immune interventions in HIV infection. Carcelain G; Autran B Immunol Rev; 2013 Jul; 254(1):355-71. PubMed ID: 23772631 [TBL] [Abstract][Full Text] [Related]
2. Toward a cure for HIV--Seeking effective therapeutic vaccine strategies. Autran B Eur J Immunol; 2015 Dec; 45(12):3215-21. PubMed ID: 26542079 [TBL] [Abstract][Full Text] [Related]
3. Immunotherapy and therapeutic vaccines in HIV infection. García F; Ruiz L; López-Bernaldo de Quirós JC; Moreno S; Domingo P Enferm Infecc Microbiol Clin; 2005 Jul; 23 Suppl 2():84-104. PubMed ID: 16373008 [TBL] [Abstract][Full Text] [Related]
4. Vaccine and immunotherapeutic interventions. Pantaleo G; Lévy Y Curr Opin HIV AIDS; 2013 May; 8(3):236-42. PubMed ID: 23478912 [TBL] [Abstract][Full Text] [Related]
5. [Immune-based therapies and HIV infection]. Weiss L Ann Med Interne (Paris); 2002 Jun; 153(4):227-36. PubMed ID: 12218888 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic vaccines against HIV infection. García F; León A; Gatell JM; Plana M; Gallart T Hum Vaccin Immunother; 2012 May; 8(5):569-81. PubMed ID: 22634436 [TBL] [Abstract][Full Text] [Related]
7. Long-term persistence of vaccination and HAART to human immunodeficiency virus (HIV). Boström AC; Hejdeman B; Matsuda R; Fredriksson M; Fredriksson EL; Bratt G; Sandström E; Wahren B Vaccine; 2004 Apr; 22(13-14):1683-91. PubMed ID: 15068851 [TBL] [Abstract][Full Text] [Related]
8. Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial. Gudmundsdotter L; Wahren B; Haller BK; Boberg A; Edbäck U; Bernasconi D; Buttò S; Gaines H; Imami N; Gotch F; Lori F; Lisziewicz J; Sandström E; Hejdeman B Vaccine; 2011 Jul; 29(33):5558-66. PubMed ID: 21300092 [TBL] [Abstract][Full Text] [Related]
10. Immune therapy: non-highly active antiretroviral therapy management of human immunodeficiency virus-infected patients. Mitsuyasu R J Infect Dis; 2002 May; 185 Suppl 2():S115-22. PubMed ID: 12001032 [TBL] [Abstract][Full Text] [Related]
11. HIV immunotherapy comes of age: implications for prevention, treatment and cure. Routy JP; Mehraj V; Cao W Expert Rev Clin Immunol; 2016; 12(2):91-4. PubMed ID: 26629806 [TBL] [Abstract][Full Text] [Related]
12. An HIV-based lentiviral vector as HIV vaccine candidate: Immunogenic characterization. Lemiale F; Asefa B; Ye D; Chen C; Korokhov N; Humeau L Vaccine; 2010 Feb; 28(8):1952-61. PubMed ID: 20188251 [TBL] [Abstract][Full Text] [Related]
13. A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. García F; Climent N; Guardo AC; Gil C; León A; Autran B; Lifson JD; Martínez-Picado J; Dalmau J; Clotet B; Gatell JM; Plana M; Gallart T; Sci Transl Med; 2013 Jan; 5(166):166ra2. PubMed ID: 23283367 [TBL] [Abstract][Full Text] [Related]
14. Novel CD8+ T cell-based vaccine stimulates Gp120-specific CTL responses leading to therapeutic and long-term immunity in transgenic HLA-A2 mice. Nanjundappa RH; Wang R; Xie Y; Umeshappa CS; Xiang J Vaccine; 2012 May; 30(24):3519-25. PubMed ID: 22484292 [TBL] [Abstract][Full Text] [Related]
15. Dendrimers as nonviral vectors in dendritic cell-based immunotherapies against human immunodeficiency virus: steps toward their clinical evaluation. Vacas-Córdoba E; Climent N; De La Mata FJ; Plana M; Gómez R; Pion M; García F; Muñoz-Fernández MÁ Nanomedicine (Lond); 2014 Dec; 9(17):2683-702. PubMed ID: 25529571 [TBL] [Abstract][Full Text] [Related]
16. Understanding HIV infection for the design of a therapeutic vaccine. Part II: Vaccination strategies for HIV. de Goede AL; Vulto AG; Osterhaus AD; Gruters RA Ann Pharm Fr; 2015 May; 73(3):169-79. PubMed ID: 25528627 [TBL] [Abstract][Full Text] [Related]
17. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients. Van Gulck E; Vlieghe E; Vekemans M; Van Tendeloo VF; Van De Velde A; Smits E; Anguille S; Cools N; Goossens H; Mertens L; De Haes W; Wong J; Florence E; Vanham G; Berneman ZN AIDS; 2012 Feb; 26(4):F1-12. PubMed ID: 22156965 [TBL] [Abstract][Full Text] [Related]
18. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients. Lévy Y; Gahéry-Ségard H; Durier C; Lascaux AS; Goujard C; Meiffrédy V; Rouzioux C; El Habib R; Beumont-Mauviel M; Guillet JG; Delfraissy JF; Aboulker JP; AIDS; 2005 Feb; 19(3):279-86. PubMed ID: 15718838 [TBL] [Abstract][Full Text] [Related]
19. Immune responses to a recombinant human immunodeficiency virus type 1 (HIV-1) gpl60 vaccine among adults with advanced HIV infection. Massachusetts gp160 Working Group. DeMaria A; Kunches L; Mayer K; Cohen C; Epstein P; Werner B; Day J; DeCristofaro J; Landers S; Tang Y; Coady W J Hum Virol; 2000; 3(4):182-92. PubMed ID: 10990166 [TBL] [Abstract][Full Text] [Related]
20. [Immunopathogenesis and therapeutic immunization in HIV-infection]. Kran AM; Kvale D Tidsskr Nor Laegeforen; 2006 Nov; 126(23):3112-6. PubMed ID: 17160117 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]